Regulatory Strategy in the EAEU and rest of CIS Countries

Webinar: Regulatory Strategy in the EAEU and Rest of CIS Countries

Regulatory strategy in EAEU and CIS regions differ from other regions as market access to these countries can be a real challenge due to various local regulations. However, it is only a matter of experience and adequate know-how.

This webinar focuses on choosing your regulatory strategy for Eurasian Economic Union and Commonwealth of Independent States, best practices and practical tips for market access and current regulatory status and GMP requirements.

 

You will learn about:

1. Commonwealth of Independent States

  • Differences and overlaps with EAEU

2. Regulatory strategy in the EAEU

  • Current status and main challenges
  • Practical tips

3. Regulatory strategy in the CIS region

  • What is the current status?
  • Best practices and key tips for main challenges
  • GMP requirements in EAEU and CIS

 

Entering EAEU or CIS markets?

Make use of our experts’ know-how to access new markets. Explore your options in a chat with one of our experts.

Who should attend?

  • Global and regional RA Managers
  • Regulatory Strategy Managers
  • RA Partnerships Operations Manager
  • QA Managers supporting RA
  • RA Healthcare Compliance Managers

Duration: 25 min.

Speaker: Regulatory Affairs Project Manager, Nargiz Asgarova, who will share her expertise on regulatory strategy in EAEU and CIS regions.

Nargiz Asgarova, BSc, MBA

Nargiz Asgarova, BSc, MBA

Regulatory Affairs Project Manager

Other content that might interest you:

Marketing Authorization Process in Russia

Marketing Authorization Process in Russia

Cultural and language problems are a frequent stumbling block for multinational corporations seeking to register drugs in Russia. Additionally, the Marketing Authorization process in Russia is highly complex, and the paperwork frequently changes as the regulatory...

read more
Drug Registration in Russia

Drug Registration in Russia

 Overview of drug registration in Russia The Russian pharmaceutical industry is expected to exceed two trillion Russian rubles in 2020, representing a roughly 10% growth over the previous year. Pharmaceutical revenues are expected to reach 2.35 trillion Russian rubles...

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information